



(51) International Patent Classification:

C07C 233/79 (2006.01) **C07D 277/42** (2006.01)
C07C 255/58 (2006.01) **A61K 31/166** (2006.01)
C07C 311/39 (2006.01) **A61K 31/427** (2006.01)
C07D 213/74 (2006.01) **A61K 31/44** (2006.01)
C07D 213/75 (2006.01) **A61P 1/00** (2006.01)
C07D 213/84 (2006.01)

(21) International Application Number:

PCT/EP2009/060150

(22) International Filing Date:

5 August 2009 (05.08.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

08162006.4	7 August 2008 (07.08.2008)	EP
09150543.8	14 January 2009 (14.01.2009)	EP
61/205,139	14 January 2009 (14.01.2009)	US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BEATTIE, David** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham West Sussex RH12 5AB (GB). **COLSON, Anny-Odile** [US/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham West Sussex RH12 5AB (GB). **CULSHAW, Andrew James** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham West Sussex RH12 5AB (GB). **SHARP, Lisa** [US/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham West Sussex RH12 5AB (GB). **STANLEY, Emily** [GB/GB]; Novartis Hor-

sham Research Centre, Wimblehurst Road, Horsham West Sussex RH12 5AB (GB). **SVIRIDENKO, Lilya** [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham West Sussex RH12 5AB (GB).

(74) Agent: **VOEGELI-LANGE, Regina**; Novartis Pharma Ag, Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: CYCLOHEXYL AMIDE DERIVATIVES AND THEIR USE AS CRF-1 RECEPTOR ANTAGONISTS

(57) Abstract: There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF₁) receptor antagonists.

